Gastrin, inflammation, and carcinogenesis

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 1, 2010, Pages 33-39

  Chao, Celia ^a   Hellmich, Mark R ^a  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

CCK2 receptors; Gastrin; Gastrointestinal cancers; Helicobacter pylori; Inflammation; Progastrin

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; ACETYLSALICYLIC ACID; CELECOXIB; CHOLECYSTOKININ B RECEPTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEVAZEPIDE; GASTRIN; INTERLEUKIN 8; NONSTEROID ANTIINFLAMMATORY AGENT; NS 298; NS298; OMEPRAZOLE; PROGLUMIDE; UNCLASSIFIED DRUG;

CANCER GROWTH; CARCINOGENESIS; CELL ACTIVITY; CELL DAMAGE; CELL REGENERATION; CELL STRESS; CELL TYPE; COLORECTAL CANCER; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM INFLAMMATION; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION REGULATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; IMMUNOCOMPETENT CELL; MICROENVIRONMENT; MODULATION; MOLECULAR INTERACTION; NONHUMAN; POSITIVE FEEDBACK; RECEPTOR UPREGULATION; RECTUM CANCER; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER;

ANIMALS; COCARCINOGENESIS; COLORECTAL NEOPLASMS; CYTOKINES; FEEDBACK, PHYSIOLOGICAL; GASTRINS; GASTRITIS; GASTROINTESTINAL NEOPLASMS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES; RECEPTOR, CHOLECYSTOKININ B;

EID: 75149182334     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328333faf8     Document Type: Review

References (51)

1. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutat Res 2008; 659:15-30.
2. Black JW. Reflections on some pilot trials of gastrin receptor blockade in pancreatic cancer. Eur J Cancer 2009; 45:360-364.
3. Laverman P, Roosenburg S, Gotthardt M, et al. Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. Eur J Nucl Med Mol Imaging 2008; 35:386-392.
4. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature 2008; 454:436-444.
5. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392:402-405.
6. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process: First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735-6740.
7. Chiba T, Marusawa H, Seno H, et al. Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol 2008; 23:1175-1181.
8. Houghton J, Stoicov C, Nomura S, et al. Gastric cancer originating from bone marrow-derived cells. Science 2004; 306:1568-1571.
9. Smythies LE, Waites KB, Lindsey JR, et al. Helicobacter pylori-induced mucosal inflammation is Th1 mediated and exacerbated in IL-4, but not IFN-gamma, gene-deficient mice. J Immunol 2000; 165:1022-1029.
10. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134:1842-1860.
11. Lehmann FS, Golodner EH, Wang J, et al. Mononuclear cells and cytokines stimulate gastrin release from canine antral cells in primary culture. Am J Physiol 1996; 270:G783-G788.
12. Takaishi S, Tu S, Dubeykovskaya ZA, et al. Gastrin is an essential cofactor for Helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice. Am J Pathol 2009; 175:365-375.
13. Wang TC, Dangler CA, Chen D, et al. Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 2000; 118:36-47.
14. Orlando LA, Lenard L, Orlando RC. Chronic hypergastrinemia: causes and consequences. Dig Dis Sci 2007; 52:2482-2489.
15. Steele IA, Dimaline R, Pritchard DM, et al. Helicobacter and gastrin stimulate Reg1 expression in gastric epithelial cells through distinct promoter elements. Am J Physiol Gastrointest Liver Physiol 2007; 293:G347-G354.
16. Thorburn CM, Friedman GD, Dickinson CJ, et al. Gastrin and colorectal cancer: a prospective study. Gastroenterology 1998; 115:275-280.
17. Smith AM, Watson SA. Gastrin and gastrin receptor activation: an early event in the adenoma-carcinoma sequence. Gut 2000; 47:820-824.
18. Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 2001; 1:55-67.
19. Koh TJ, Bulitta CJ, Fleming JV, et al. Gastrin is a target of the beta-catenin/ TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest 2000; 106:533-539.
20. Franco AT, Israel DA, Washington MK, et al. Activation of beta-catenin by carcinogenic Helicobacter pylori. Proc Natl Acad Sci U S A 2005; 102: 10646-10651.
21. Franco AT, Johnston E, Krishna U, et al. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res 2008; 68:379-387.
22. Chell S, Kaidi A, Williams AC, et al. Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/ treatment of colorectal cancer. Biochim Biophys Acta 2006; 1766:104-119.
23. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A 1992; 89:7384-7388.
24. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146:376-389.
25. Grosch S, Maier TJ, Schiffmann S, et al. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006; 98:736-747.
26. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NFkappaB pathway. J Biol Chem 1999; 274:27307-27314.
27. Abdalla SI, Lao-Sirieix P, Novelli MR, et al. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 2004; 10:4784-4792.
28. Guo YS, Cheng JZ, Jin GF, et al. Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways. Evidence for involvement of ERK5 kinase and transactivation of the epidermal growth factor receptor. J Biol Chem 2002; 277:48755-48763.
29. Sun WH, Zhu F, Chen GS, et al. Blockade of cholecystokinin-2 receptor and cyclooxygenase-2 synergistically induces cell apoptosis, and inhibits the proliferation of human gastric cancer cells in vitro. Cancer Lett 2008; 263: 302-311.
30. Subramaniam D, Ramalingam S, May R, et al. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology 2008; 134:1070-1082.
31. Walduck AK, Weber M, Wunder C, et al. Identification of novel cyclooxygenase-2-dependent genes in Helicobacter pylori infection in vivo. Mol Cancer 2009; 8:22.
32. Aly A, Shulkes A, Baldwin GS. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta 2004; 1704:1-10.
33. Konturek PC, Rembiasz K, Burnat G, et al. Effects of cyclooxygenase-2 inhibition on serum and tumor gastrins and expression of apoptosis-related proteins in colorectal cancer. Dig Dis Sci 2006; 51:779-787.
34. Jin G, Ramanathan V, Quante M, et al. Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. J Clin Invest 2009; 119:2691-2701.
35. SinghP,WuH,ClarkC,etal.Annexin IIbindsprogastrinandgastrin-likepeptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells. Oncogene 2007; 26:425-440.
36. Dubeykovskiy A,Nguyen T,Dubeykovskaya Z, et al. Flowcytometric detection of progastrin interaction with gastrointestinal cells. Regul Pept 2008; 151:106-114.
37. Amara A, Lorthioir O, Valenzuela A, et al. Stromal cell-derived factor-1alpha associates with heparan sulfates through the first beta-strand of the chemokine. J Biol Chem 1999; 274:23916-23925.
38. Haigh CR, Attwood SE, Thompson DG, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124:615-625.
39. Ottewell PD, Duckworth CA, Varro A, et al. Gastrin increases murine intestinal crypt regeneration following injury. Gastroenterology 2006; 130:1169-1180.
40. AshurstHL,Varro A,Dimaline R.Regulationofmammaliangastrin/CCKreceptor (CCK2R) expression in vitro and in vivo. Exp Physiol 2008; 93:223-236.
41. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6:392-401.
42. Chao C, Tallman ML, Ives KL, et al. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005; 129:313-321.
43. Mezey E, Palkovits M. Localization of targets for antiulcer drugs in cells of the immune system. Science 1992; 258:1662-1665.
44. Sacerdote P, Wiedermann CJ, Wahl LM, et al. Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 1991; 12:167-176.
45. Schmitz F, Schrader H, Otte J, et al. Identification of CCK-B/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul Pept 2001; 101:25-33.
46. Schmitz F, Otte JM, Stechele HU, et al. CCK-B/gastrin receptors in human colorectal cancer. Eur J Clin Invest 2001; 31:812-820.
47. Carrasco M, Hernanz A, De La Fuente M. Effect of cholecystokinin and gastrin on human peripheral blood lymphocyte functions, implication of cyclic AMP and interleukin 2. Regul Pept 1997; 70:135-142.
48. De la Fuente M, Carrasco M, Hernanz A. Modulation of human neutrophil function in vitro by gastrin. J Endocrinol 1997; 153:475-483.
49. Alvarez A, Ibiza S, Hernandez C, et al. Gastrin induces leukocyte-endothelial cell interactoins in vivo and contributes to the inflammation caused by Helicobacter pylori. FASEB J 2006; 20:E1742-E1752.
50. Kim SO, Chao C, Townsend CM Jr, et al. Interferon-g induces CCK2 receptor expression in monocytes and bone marrow-derived cells. Gastroenterology 2009; 136:A398.
51. Reubi JC, Waser B, Schmassmann A, et al. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastro-intestinal adenocarcinoma samples: where are they really located? Int J Cancer 1999; 81:376-386.